Department of Radiology
Found 38 results
Filters: Author is Larson, Steven M  [Clear All Filters]
2023
Chung SK, Vargas DBurnes, Chandler CS, Katugampola S, Veach DR, McDevitt MR, Seo SH, Vaughn BA, Rinne SS, Punzalan B et al..  2023.  Efficacy of HER2-Targeted Intraperitoneal 225Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis.. J Nucl Med. 64(9):1439-1445.
Kurtz K, Eibler L, Dacek MM, Carter LM, Veach DR, Lovibond S, Reynaud E, Qureshy S, McDevitt MR, Bourne C et al..  2023.  Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.. Theranostics. 13(15):5469-5482.
Bodei L, R Tuttle M, Grewal RK, Mauguen A, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VSudar, Osborne JR, Haque S et al..  2023.  Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs.. Eur J Nucl Med Mol Imaging.
Mauguen A, Grewal RK, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VSudar, Osborne J, Haque S, Z Y Wong B, Ghossein RA et al..  2023.  The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.. Eur J Nucl Med Mol Imaging. 50(10):2971-2983.
2022
Chandler CS, Bell MM, Chung SK, Veach DR, Fung EK, Punzalan B, Vargas DBurnes, Patel M, Xu H, Guo H-F et al..  2022.  Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis.. Mol Cancer Ther. 21(1):125-137.
2021
Cheal SM, Patel M, Yang G, Veach DR, Xu H, Guo H-F, Zanzonico PB, Axworthy DB, Cheung N-KV, Ouerfelli O et al..  2021.  Correction to An -Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy.. Bioconjug Chem. 32(2):394.
Dacek MM, Veach DR, Cheal SM, Carter LM, McDevitt MR, Punzalan B, Vargas DBurnes, Kubik TZ, Monette S, Santich BH et al..  2021.  Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications.. Bioconjug Chem. 32(4):649-654.
Yerrabelli RS, He P, Fung EK, Kramer K, Zanzonico PB, Humm JL, Guo H, Pandit-Taskar N, Larson SM, Cheung N-KV.  2021.  IntraOmmaya compartmental radioimmunotherapy using I-omburtamab-pharmacokinetic modeling to optimize therapeutic index.. Eur J Nucl Med Mol Imaging. 48(4):1166-1177.
Santich BH, Cheal SM, Ahmed M, McDevitt MR, Ouerfelli O, Yang G, Veach DR, Fung EK, Patel M, Vargas DBurnes et al..  2021.  A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy.. Clin Cancer Res. 27(2):532-541.
2020
Cheal SM, Patel M, Yang G, Veach D, Xu H, Guo H-F, Zanzonico PB, Axworthy DB, Cheung N-KV, Ouerfelli O et al..  2020.  An -Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy.. Bioconjug Chem. 31(3):501-506.
Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, Veach DR, Bell M, Ahad A, Vargas DBurnes et al..  2020.  Alpha radioimmunotherapy using Ac-proteus-DOTA for solid tumors - safety at curative doses.. Theranostics. 10(25):11359-11375.
2019
Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, Zhang Z, Lyashchenko SK, Fung AM, Pentlow KS et al..  2019.  Biodistribution and Dosimetry of Intraventricularly Administered I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.. J Nucl Med. 60(12):1794-1801.
Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, Cheal SM, O'Donoghue JA, Ruan S, Ragupathi G et al..  2019.  Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.. J Nucl Med. 60(11):1517-1523.
O'Donoghue JA, Danila DC, Pandit-Taskar N, Beylergil V, Cheal SM, Fleming SE, Fox JJ, Ruan S, Zanzonico PB, Ragupathi G et al..  2019.  Pharmacokinetics and Biodistribution of a [Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.. Mol Pharm. 16(7):3083-3090.
2018
Cheal SM, Ruan S, Veach DR, Longo VA, Punzalan BJ, Wu J, Fung EK, Kelly MP, Kirshner JR, Giurleo JT et al..  2018.  ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.. Mol Pharm. 15(6):2133-2141.
Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW et al..  2018.  Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.. JAMA Oncol. 4(2):217-224.
Cheal SM, Xu H, Guo H-F, Patel M, Punzalan B, Fung EK, Lee S-G, Bell M, Singh M, Jungbluth AA et al..  2018.  Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.. Theranostics. 8(18):5106-5125.
2017
Cheal SM, Fung EK, Patel M, Xu H, Guo H-F, Zanzonico PB, Monette S, K Wittrup D, Cheung N-KV, Larson SM.  2017.  Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.. J Nucl Med. 58(11):1735-1742.
2016
Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M et al..  2016.  First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.. J Nucl Med. 57(12):1858-1864.
Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR et al..  2016.  Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling.. EJNMMI Res. 6(1):7.
Cheal SM, Xu H, Guo H-F, Lee S-G, Punzalan B, Chalasani S, Fung EK, Jungbluth A, Zanzonico PB, Carrasquillo JA et al..  2016.  Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.. Eur J Nucl Med Mol Imaging. 43(5):925-937.
2015
Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal SM, Guo H-F, Larson SM, Cheung N-KV.  2015.  Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.. J Biol Chem. 290(50):30018-29.
Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AMak et al..  2015.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.. Clin Cancer Res. 21(23):5277-85.
2014
Cheal SM, Yoo B, Boughdad S, Punzalan B, Yang G, Dilhas A, Torchon G, Pu J, Axworthy DB, Zanzonico P et al..  2014.  Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy.. Mol Pharm. 11(2):400-16.
Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, Larson SM.  2014.  Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcino. Eur J Nucl Med Mol Imaging. 41(5):985-94.